NCT00936559TerminatedPhase 1
Randomized, Single-Blind, Standard Of Care Control, Dose-Escalating, Multicenter, Safety Study Of BMP-655/ACS As An Adjuvant Therapy For Treatment Of Full Thickness Rotator Cuff Tears Treated By Means Of An Open Surgical Procedure
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Sponsor
- Pfizer
- Enrollment
- 13
- Locations
- 5
- Primary Endpoint
- Abnormal X-rays, MRIs, CT scans, physical examination of limb, functional evaluations, AE/SAE, vital signs, subject assessment of pain, lab tests
Study Overview
Brief Summary
Study to assess the safety of 3 differing concentrations of BMP-655/ACS in subjects with full thickness Rotator Cuff Tears (RCTs).
Detailed Description
This decision to terminate enrollment in this study is based on the company's change in prioritization for the portfolio and was not due to any safety concerns, or regulatory interactions.
Patients already enrolled in the study, should continue to complete assessments as described in the protocol.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 25 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male subjects and surgically sterile or postmenopausal female subjects between the ages of 25 and 75 years old with specific full-thickness RCTs identified on closed MRI within 3 months before surgery.
Exclusion Criteria
- •Subjects who have had previous surgical intervention to the shoulder joint under study or additional injury requiring surgical repair or a history of shoulder dislocation in the affected shoulder or physical examination findings of instability in either shoulder
- •Subjects who are unable to complete functional evaluations because of any other concurrent injuries or impairment in either the arm
- •Subjects identified with specific fatty infiltration of their RC muscles on MRI taken within 3 months prior to surgical repair
- •Subjects with moderate or severe degenerative arthritis of the shoulder under study or any bone abnormalities as confirmed on a radiograph
- •Subjects with rheumatologic conditions affecting the shoulder joints or autoimmune disorders, treated with more than 3 corticosteroid injections in the shoulder under study within 1 year of planned surgery, any recent corticosteroid injection in the shoulder or currently receiving oral corticosteroids
- •Subjects who are either unwilling or unable to undergo examination with closed MRI.
Outcomes
Primary Outcomes
Abnormal X-rays, MRIs, CT scans, physical examination of limb, functional evaluations, AE/SAE, vital signs, subject assessment of pain, lab tests
Time Frame: 1 year
Secondary Outcomes
- Investigator Questionnaire(1 year)
Investigators
Study Sites (5)
Loading locations...
Similar Trials
Completed
Phase 3
A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque PsoriasisPlaque PsoriasisNCT04607980Amgen563
Terminated
Phase 1
Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)Type 2 Diabetes MellitusNCT00707590Bristol-Myers Squibb120
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)Relapsed or Refractory Multiple Myeloma (RRMM)NCT06615479Juno Therapeutics, Inc., a Bristol-Myers Squibb Company440
Completed
Phase 1
Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant TumorsMalignant TumorsNCT02534506Bristol-Myers Squibb18
Completed
Phase 1
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant MelanomaMalignant MelanomaNCT01024231Bristol-Myers Squibb127